Clinical Trials Archive

A building with a stone facade displays a sign that reads
J-Valve to Treat Aortic Regurgitation Via Transcatheter Therapy
A building with a stone facade displays a sign that reads
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer (RUBY)
A building with a stone facade displays a sign that reads
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A building with a stone facade displays a sign that reads
Natera/Yanuvia_SCORE_Moorthy
A building with a stone facade displays a sign that reads
GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis Post-Approval Study
A building with a stone facade displays a sign that reads
Biomarkers for Pancreatic Cancer Diagnosis: Prospective Cohort Study for the Early Detection of Pancreatic Ductal Adenocarcinoma
A building with a stone facade displays a sign that reads
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
A building with a stone facade displays a sign that reads
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
A building with a stone facade displays a sign that reads
A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors
A building with a stone facade displays a sign that reads
A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3Kα Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors